Serum interleukin‐10 level is increased and correlated positively with disease severity in patients with dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoid
- 20 October 2024
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (1) , 122-131
Abstract
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease with a linear deposit of autoantibodies at the epidermal basement membrane zone. It was reported that diabetes patients who took a dipeptidyl peptidase‐4 inhibitor (DPP4i), an oral antidiabetic drug, had an increased incidence of BP. However, data on DPP4i‐related BP are limited. In our study, we measured serum levels of various cytokines using LEGENDplex and assessed correlations of these serum levels with clinical severity and laboratory data. Serum samples obtained from BP patients who visited our hospital from June 2016 to February 2023 were collected in this study. Patients' background, characteristics, and clinical data were retrospectively collected from their charts. Serum samples from 27 patients with DPP4i‐unrelated BP, 17 patients with DPP4i‐related BP, and 13 healthy controls were analyzed. Patients with DPP4i‐related BP had lower score of Bullous Pemphigoid Disease Area Index (BPDAI)‐erythema/urticaria, lower number of circulating eosinophils, and lower titer of anti‐BP180 antibody than patients with DPP4i‐unrelated BP. The serum interleukin (IL)‐6 level was significantly higher in patients with DPP4i‐related BP than in healthy controls ( P = 0.0037). The serum IL‐10 level was significantly higher in patients with DPP4i‐related BP than in patients with DPP4i‐unrelated BP and in healthy controls ( P = 0.0006, P = 0.0448), and was positively correlated with the BPDAI‐blister/erosions score ( r = 0.757, P = 0.001), BPDAI‐erythema/urticaria score ( r = 0.616, P = 0.013), and BPDAI‐total score ( r = 0.833, P < 0.001) in patients with DPP4i‐related BP. In conclusion, patients with DPP4i‐related BP had increased serum levels of IL‐6 and IL‐10 compared with healthy controls and positive correlations between the serum IL‐10 level and BPDAI scores reflecting clinical severity, indicating that the serum IL‐10 level is a potential objective biomarker of disease severity in patients with DPP4i‐related BP.Keywords
This publication has 32 references indexed in Scilit:
- Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopesJournal of Dermatological Science, 2021
- Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoidJournal of Dermatological Science, 2020
- Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoidAutoimmunity Reviews, 2019
- Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With DiabetesJAMA Dermatology, 2018
- Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry StudyJournal of Investigative Dermatology, 2018
- Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous PemphigoidJournal of Investigative Dermatology, 2016
- CD26 costimulatory blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expressionThe Journal of Heart and Lung Transplantation, 2016
- A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patientsMetabolism, 2013
- PRESENCE OF INTERLEUKIN 10 IN THE SERUM AND BLISTER FLUID OF PATIENTS WITH PEMPHIGUS VULGARIS AND PEMPHIGOIDCytokine, 2000
- Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoidArchives of Dermatological Research, 1996